

Full Length Research Paper

Diversity of respiratory yeast from HIV infected patients with tuberculosis, their drug resistances and biofilm formation

Samie A.* and Mashao M. B.

University of Venda, Department of Microbiology, Private Bag X5050, Thohoyandou 0950, Limpopo, South Africa.

Accepted 22 November, 2011

Although several fungal organisms are known to infect human immunodeficiency virus (HIV) and acquired immune deficiency syndrome (AIDS) patients, the diversity of yeast pathogens that infect individuals in South Africa is not known. In the present study sputum samples were collected from HIV positive patients who presented at the hospital with tuberculosis (TB). The yeasts organisms were isolated using potato dextrose agar and identified by germ tube test, CHROMagar and Urease based agar. The production of biofilm was tested using the microtitre plate method. The activities of amphotericin B, fluconazole and ketaconazole were tested using the standard disc diffusion method. Out of the 91 patients, 53 (58%) were females. Thirty seven patients (41%) were aged between 26 and 45 years old. The most common isolates were *Cryptococcus neoformans* (28%), followed by *Candida parapsilopsis* (19%), *Candida krusei* (16%), *Candida albicans* (15%) and *Candida tropicalis* (13%). The different species showed high levels of drug resistance to fluconazole (74.0%), ketaconazole (74.0%) and amphotericin B (33.7%). Biofilm production was observed in 28% of all the isolates and was not associated with drug resistance ($p > 0.01$). This study showed that the lungs of HIV patients with TB are often colonized by opportunistic yeasts such as *Cryptococcus* and *Candida* spp. The most common isolates included *C. neoformans*, *C. parapsilopsis*, *C. krusei* and *C. albicans*, and amphotericin B was the most active drug against these organisms. Further studies are needed to determine the potential impact of these organisms on the emergence of multi-drug resistant (MDR) and extensively drug resistant tuberculosis (XDR TB).

Key words: *Candida* spp, *Cryptococcus neoformans*, co-infections, epidemiology, fungal infections, HIV and AIDS, opportunistic infections, tuberculosis, Venda and South Africa.

INTRODUCTION

Fungal infections are a major cause of morbidity and mortality in the immunocompromised host and examples of fungal pathogens responsible for such infections include *Pneumocystis jiroveci*, several *Candida* spp., *Cryptococcus* spp. and *Penicillium* spp. (Pfaller and Diekema, 2006). In the last two decades the frequency of invasive fungal infections has increased remarkably

(Barnes, 2008). Respiratory infections are among the most common causes of morbidity and mortality among human immunodeficiency virus (HIV) and acquired immune deficiency syndrome (AIDS) patients and tuberculosis is one of the most common infections among HIV and AIDS patients (Zumla et al., 2009; Naidoo et al., 2011; Rajasekaran et al., 2009). Over the past decade, studies have indicated that TB is the most common opportunistic infection in HIV patients particularly those with CD4 counts less than 200 cells/mm³ (Karim et al., 2009).

The prevalence of TB-HIV co-infection is high and reaches 65% for example in Uganda while in South

*Corresponding author. E-mail: samieamidou@yahoo.com, samie.amidou@univen.ac.za, beautymashao@gmail.com. Tel: +27159628186, +27760952916. Fax: 27 15 962 4749.

Africa; up to 75% of the TB patients are co-infected with HIV (Bazira et al., 2011; Heunis et al., 2011). In South Africa, several studies have demonstrated the impact of HIV and TB co-infection with more than 20 times increase in mortality among TB-HIV co-infected cases compared to non-HIV infected individuals (Ramogale et al., 2007; Grange et al., 2010). However, very few studies have documented the occurrence of yeast infections among TB infected HIV patients (Jarvis et al., 2010).

The factors contributing to the pathogenesis of *Candida* and its progression in HIV positive patients are poorly understood, but may include biofilm production, an interrelationship between HIV and *Candida* and or a dysfunctioning in the local immunity superimposed on weakened cell-mediated immunity and depletion of CD4 T cells (Egusa et al., 2008; Alby and Bennett, 2009). Clinical diagnosis is often presumptive. Therefore laboratory diagnosis is required for conclusive identification and advice for therapy. However, microbiological examination is rarely conducted for patients attending health care centres in the Limpopo, South Africa and consequently little is known about the different types of yeast organisms occurring in the Limpopo Province as well as the antifungal susceptibility profiles of South African yeast isolates (Blignaut et al., 2002). As such it is not certain that treatments being administered to individuals for fungal infections are taking appropriate effect. The isolation and identification of opportunistic yeast pathogens from patients presenting symptoms associated with these agents is important for establishing the appropriate treatment regimen. The present study investigated the occurrence and diversity as well as drug susceptibility profiles of yeast isolates and their biofilm production characteristics among HIV and AIDS patients presenting with TB in treatment centers in the Limpopo Province.

MATERIALS AND METHODS

Ethical considerations

Ethical clearance for the present study was obtained from the University of Venda Health Safety and Ethics committee and authorization to conduct the study in public health facilities was granted by the Department of Health in Limpopo. The objectives of the study were explained to the patients and the patients were required to sign a consent form if they agreed to participate in the study. Samples used in the present study were de-identified sputum samples submitted for analysis to the hospital laboratory to ensure confidentiality of the patients.

Patients and sample collections

De-identified sputum samples, were collected from HIV positive patients visiting hospitals with respiratory syndromes such as cough or persistent cough, night sweating, fever or weight loss. After collection, the samples were inoculated on potato dextrose agar and incubated over night at 37°C. After incubation the samples were collected in a cooler box and transported from the hospital to the Microbiology Department at the University of Venda for further

laboratory analysis.

HIV and TB diagnosis

The study participants were screened for antibodies to HIV with the OraQuick HIV1/2 (OraSure Technologies, USA), using oral fluids, and with Determine HIV1/2 (Abbott Laboratories, USA), employing finger prick whole blood according to manufacturer's instruction as described previously (Samie et al., 2010). TB diagnosis was performed at the Hospital by the acid fast staining as previously described (Cattamanchi et al., 2009).

Yeast isolation and identification

The pure colonies from the plates were cultured in Sabouraud dextrose agar (SDA) at 37°C over night. Identification of the yeast isolates was done by noting colonial morphology, color, size, texture, and topography of the colonies. Urea agar based method was used for the identification of *Cryptococcus neoformans*. Chromogenic *Candida* agar (CHROMagar) was used to identify different species of *Candida* by noting the color change as previously described (Odds and Bernaerts, 1994).

The germ tube test was done by adding 50 µl of broth culture to 450 µl of horse blood serum in a microcentrifuge tube and incubating at 37°C for 3 h. After incubation the culture was suspended on a glass slide and viewed under a microscope at 40x magnification.

Biofilm production assay

All the microorganisms were tested for the production of biofilm using the microtiter plate method as described by Christensen et al. (1982). Briefly, suspension of cultures were prepared in brain heart infusion (BHI) DIFCO™ broth with 1% sucrose and incubated over night. After washing with phosphate buffered saline (PBS), the plates were stained with 1% crystal violet, incubated at room temperature for 15 min, and the plates were washed again and incubated at 37°C for 30 min to dry. Then 200 µl of a mixture of 80% ethanol and 20% acetone was added to the plates to solubilise the crystal violet, the plates were incubated at room temperature for 20 min and the results were read at 490 nm using the ELISA reader.

Antifungal susceptibility test by disc diffusion method

The activity of some commercial available drugs (antifungal agents) was tested using the disc diffusion method which was performed according to the Clinical Laboratory Standards Institute (CLSI). The antifungal agents used were: Amphotericin B, fluconazole and ketoconazole. Petri dishes with potato dextrose agar (PDA) were inoculated with the culture using sterile swabs and a disc (antifungal drug) of each antifungal agent was placed on the cultured medium and incubated at 37°C over night. After incubation, the zone of inhibition (which is the diameter around the antifungal disc where the growth of the microorganism was inhibited) was measured using a ruler.

Statistical analysis

The data acquired were entered in Microsoft Excel sheet, and analysis was conducted by using statistical package for social sciences (SPSS) program version 17.1. Chi-square was used to determine the correlation between the different tests performed, and p values were used to determine the significance of the

Table 1. Distribution of the different types of respiratory yeast infections among female and male HIV and AIDS patients co-infected with TB of different age groups.

Type of infections	Unknown age		< 25		26 – 45		>45		U	Total
	Female	Male	Female	Male	Female	Male	Female	Male		
No infection	2(40%)	1(20%)	6(35%)	2(22%)	6 (33%)	6(32%)	2(15%)	0	2	27(30%)
1	2(40%)	3(60%)	7 (41%)	1 (11%)	7 (39%)	8 (42%)	8 (62%)	2 (67%)		38(42%)
2	1(20%)	1(20%)	4 (24%)	5 (56%)	4 (22%)	3 (16%)	2 (15%)	0 (%)		20(22%)
3	0	0	0	0	0	1 (5%)	1 (8%)	1 (33%)		3(3%)
4	0	0	0	1 (11%)	0	0	0	0		1(1%)
5	0	0	0	0	1 (6%)	1 (5%)	0	0		2(2%)
Total	5	5	17	9	18	19	13	3	2	91

1: Single infection (Infection by one yeast species), 2: Infection with two different species, 3: infection with three different species, 4: Infection with four different species, and 5: infection with five different species. "U"= unknown.

findings, considering p values ($p < 0.05$) as significant.

RESULTS

Demographic information on the study population

A total of 91 sputum samples were collected from patients of different age groups and different gender. Out of the 91 samples; 53 were from females, 36 from males and 2 were from unknown gender. A total of 26 samples were from individuals aged less than 25 years, 37 samples were from patients aged between 26 to 45years while 18 samples were from patients aged above 45 years. Ten samples were from individuals of unknown age.

Prevalence of yeast organisms in sputum samples from HIV and AIDS patients co-infected with TB

Out of the 91 sputum samples collected from 91

consecutive patients, a total of 104 strains of different yeast species were isolated and identified. Out of the 91 patients, 64 (70.32%) were infected with at least one yeast species. Males were more infected (75%) compared to females (69.8%) although the difference was not significant ($\chi^2 = 5.124$; $p = 0.77$). Generally the prevalence of yeast infections in the respiratory tract was higher among individuals aged above 45 years (77.7%). In this study, there were 3 males aged above 45 years and all the 3 were infected while 4 out of the 5 males of unknown age were infected. Among the females the highest rate of infection was observed among those aged above 45 years (Table 1).

Occurrence of single and multiple respiratory yeast infections among the HIV and AIDS patients co-infected with TB

Of the 91 patients, 27 (30%) were not infected with any yeast organism. Single infection defined as infection by only one yeast species was found in 38 (42%) patients while multiple infections

defined as infection with more than 1 yeast species was found in 26 (29%) of the patients. Out of all the single infections, *C. krusei* was the most common representing 14% of all infections while *C. famata* was the least common with only 1 case. Table 2 describes all the types of infections encountered, including those infected with one organism, 2, 3, 4 or 5 organisms at a time.

Species distribution among isolates infecting HIV and AIDS patients co-infected with TB

The most commonly isolated yeast was *C. neoformans* with 29 (28%) isolates followed by *Candida Parapsilosis* with 20 (19%) isolates and *Candida Krusei* with 17 (16%). *Candida albicans* was the fourth most commonly isolated yeast from the sputum of these patients with 15 (15%) isolates while the least common was *Candida guillermundii* 1 (1%) isolates. Figure 1 shows a pie chart distribution of different yeast species from sputum samples of HIV positive patients with tuberculosis.

Table 2. Frequency table for the occurrence of single and multiple respiratory yeast infections among HIV and AIDS patients co-infected with TB.

No of organism	Infections	Frequency	Percent (%)
1	<i>C. alb</i>	6	9.4
1	<i>C. fam</i>	1	1.6
1	<i>C. glab</i>	2	3.1
1	<i>C. krus</i>	9	14.1
1	<i>C. neof</i>	7	10.4
1	<i>C. para</i>	7	10.4
1	<i>C. trop</i>	6	9.4
2	<i>C. alb</i> ; <i>C. krus</i>	4	6.2
2	<i>C. alb</i> ; <i>C. lam</i>	1	1.6
2	<i>C. alb</i> ; <i>C. neof</i>	1	1.6
2	<i>C. fam</i> , <i>C. para</i>	1	1.6
2	<i>C. krus</i> ; <i>C. neof</i>	2	3.1
2	<i>C. krus</i> ; <i>C. para</i>	2	3.1
2	<i>C. krus</i> ; <i>C. trop</i>	1	1.6
2	<i>C. lam</i> ; <i>C. trop</i>	1	1.6
2	<i>C. neof</i> ; <i>C. para</i>	5	7.8
2	<i>C. neof</i> ; <i>C. trop</i>	2	3.1
3	<i>C. alb</i> ; <i>C. krus</i> ; <i>C. neof</i>	1	1.6
3	<i>C. glab</i> ; <i>C. neof</i> ; <i>C. para</i>	1	1.6
3	<i>C. krus</i> ; <i>C. neof</i> ; <i>C. trop</i>	1	1.6
4	<i>C. krus</i> ; <i>C. lam</i> ; <i>C. neof</i> ; <i>C. para</i>	1	1.6
5	<i>C. alb</i> ; <i>C. glab</i> ; <i>C. krus</i> ; <i>C. neof</i> ; <i>C. para</i>	1	1.6
5	<i>C. alb</i> ; <i>C. guil</i> ; <i>C. krus</i> ; <i>C. neof</i> ; <i>C. trop</i>	1	1.6
	Total	64	100.0

C. alb = *C. albicans*; *C. fam* = *C. famata*; *C. glab* = *C. glabrata*; *C. guil* = *C. guilliermondii*; *C. krus* = *C. krusei*; *C. para* = *C. parapsilosis*; *C. trop* = *C. tropicalis*; *C. neof* = *C. neoformans*.

Distribution of the different yeast species among HIV and AIDS patients co-infected with TB

Of all the yeast isolates *C. albicans* was more common among female patients (18%) compared to males (10%) however the difference was not statistically significant ($\chi^2 = 1.159$; $p = 0.214$). Similar situations were observed with *C. Krusei* and *Candida Tropicalis* that were more common among females than males. *C. neoformans* and *C. Parapsilosis* were more common among the males. *Candida famata* and *C. guilliermondii* were not isolated from females.

While *Candida albicans* was more common among patients aged between 26 and 45 years, the non-albicans *Candida* showed a progressive distribution among the three different age groups considered in the present study. *C. krusei* and *C. tropicalis* were more common among the individuals aged above 45 years and less common among patients less than 26 years old. On the other hand, *C. parapsilosis* was more common among individuals less than 26 years old and less common among individuals aged above 45 years, the same as *C. neoformans* which was more common among individuals

aged less than 26 years.

Although *C. albicans* was more common among females in general, the prevalence was higher among males aged above 45 years but *C. albicans* was not found among the males individuals aged less than 26 years. *C. neoformans* was more common among the males aged more than 25 years. However, it was more common among the females aged less than 26 years.

Antifungal drug resistance of respiratory yeast organisms from HIV and AIDS patients co-infected with TB

Of the 3 antifungal drugs tested, amphotericin B was the most active with only 33.7% resistance among the fungal organisms compared to 74% resistance against fluconazole and 74% against ketoconazole. Non-*C. albicans* appeared to be significantly more resistant to amphotericin B compared to *C. albicans* ($\chi^2 = 6.056$; $p = 0.048$) except *Candida glabrata* from which none of the 4 isolates was resistant to amphotericin B. All the 2 *C. famata* (100%) and the *C. guilliermondii* (100%) isolates




Figure 1. Species distribution among the yeast species (comprising *Candida* spp. and *Cryptococcus neoformans*) isolated from sputum samples of the HIV positive patients co-infected with tuberculosis at the Hospital. “C” = *Candida*; “Crypt.” = *Cryptococcus*.

Table 3. Antifungal drug resistance among respiratory yeast isolates from HIV and AIDS patients co-infected with TB in the Vhembe district.

Organisms	Ketoconazole (%)	Fluconazole (%)	Amphotericin B	Total
<i>C. albicans</i>	11 (73.3)	12 (80.0)	1 (6.7%)	15
<i>C. famata</i>	2 (100.0)	2 (100.0)	2 (100.0%)	2
<i>C. glabrata</i>	2 (50.0)	3 (75.0)	0	4
<i>C. guilliermondii</i>	1 (100.0)	1 (100.0)	1 (100.0%)	1
<i>C. krusei</i>	14 (82.4)	11 (64.7)	3 (17.6%)	17
<i>C. lambica</i>	2 (66.7)	2 (66.7)	1 (33.3%)	3
<i>C. parapsilosis</i>	13 (65.0)	15 (75.0)	11 (55.0%)	20
<i>C. tropicalis</i>	11 (84.6)	11 (84.6)	7 (53.8%)	13
<i>C. neoformans</i>	21 (72.4)	20 (69.0)	9 (31.0%)	29
Total	77 (74.0)	77 (74.0)	35 (33.7%)	104

“C”= *Candida*; “Crypt.”=*Cryptococcus*.

were resistant to amphotericin B while *C. albicans* had a resistance rate of (6.7%). *C. neoformans* had a resistance rate of 31% to amphotericin B while *C. krusei* had a resistance rate of 17% (Table 3). Resistance to fluconazole and ketoconazole was generally high among all the fungal isolates with general resistance rates of 74% for both drugs. *C. krusei* showed the least resistance to fluconazole (64.7%) while *C. glabrata* (50%) followed by *C. parapsilosis* (65%) were the least resistant

to ketoconazole.

Effect of gender and age of the HIV and AIDS patients co-infected with TB on drug resistance among the fungal isolates

Generally isolates from males were more resistant to all antibiotics compared to those isolated from females,




Figure 2. Drug resistance patterns of all the fungal isolates according to the gender of the HIV and AIDS patients co-infected with TB.

however, the difference was not significant ($p > 0.05$) (Figure 2). Isolates obtained from individuals aged less than 25 years were generally more resistant to amphotericin B compared to those isolated from individuals aged 26 and above. Resistance to fluconazole and ketoconazole were more common among isolates obtained from patients aged above 45 years. A more detailed analysis of the drug resistance rate indicated that males aged between 26 and 45 were the least resistant to amphotericin B while isolates obtained from females aged above 45 years, were the most resistant to ketoconazole.

None of the *C. albicans* isolated from males was resistant to amphotericin B while 10% of the isolates from females were resistant to amphotericin B. Similarly, *Candida lambica* isolated from females were resistant to amphotericin B as compared to those isolated from males which showed 0.0% resistance. *C. albicans*, *C. parapsilosis* and *C. tropicalis* isolated from males showed 100% resistance to fluconazole whereas, *C. lambica* and *C. glabrata* isolated from females showed 100% resistance to the same drug. All the species isolated from males showed high resistance to ketoconazole with an exception of *C. lambica* which was the only species that showed resistance in isolates from females and 0.0% resistance in isolates from males.

Multiple drug resistance among the isolates obtained from HIV and AIDS patients co-infected with TB

Multiple drug resistance (MDR) defined as the simultaneous resistance of an isolate to more than one

drug was common and 75 (72.8%) were resistant to more than 1 drug at a time. Of all the isolates tested, 19 (18.4%) were susceptible to all the 3 drug tested, 9 (8.7%) were resistant to only one drug. Forty six isolates (44.7%) were resistant to 2 drugs while 30 (28.8%) were resistant to all the three drugs at a time. Of all the yeast organisms, *C. tropicalis* showed 46.2% resistance to all the three drugs while all the 2 *C. famata* strains and the only *C. guilliermondii* strain were resistant to all the 3 drugs investigated. Of all the isolates, those obtained from males had the highest MDR rate (81.3%) compared to those isolated from females (61.5%) ($\chi^2 = 3.231$; $p = 0.057$). The rate of MDR was similar among the age groups, however, the rate of resistance to 3 drugs was higher among the isolates obtained from individuals aged less than 26 years (41.8%) compared to individuals aged 26 – 45 (21.1%) and those from individuals aged more than 45 years (26.3%). Of all the species, *C. famata* and *C. guilliermondii* were all resistant to more than 1 drug at a time. *C. glabrata* was the least resistant species with MDR while 73.3% of *C. albicans* isolates were resistant to more than 1 drug.

Biofilm production among the respiratory yeast isolates obtained from HIV and AIDS patients co-infected with TB

Biofilm production was tested among the yeast organisms and 29 (27.9%) of all the isolates were biofilm producers. Of all the organisms identified, the only *C. guilliermondii* isolate was positive for biofilm while 1 of the 2 *C. famata* and 2 of the 4 *C. glabrata* were biofilm




Figure 3. Biofilm production by the different yeast species isolated from HIV and AIDS patients co-infected with TB.

producers (Figure 3). One third of all the 15 *C. albicans* strains were biofilm producers. When all the other *Candida* spp. was considered together, biofilm production appeared only in 25% of non-*albicans Candida*. The sex and the age of the patients from whom the isolates were obtained did not have any impact on biofilm production by the isolates ($p = 0.661$ for sex and 0.158 for age). In the present study, biofilm production did not seem to have any effect on drug resistance.

DISCUSSION

Respiratory infections are commonly found among HIV and AIDS patients and the etiology varies between bacteria, viruses and fungi. Several studies have investigated the involvement of fungal pathogens in respiratory infections and most reports so far have implicated *C. albicans* as the most common agent of *Candida* pneumonia (Connolly et al., 1999). However, recent studies have reinforced the growing importance of non-*albicans Candida* such as *C. parapsilosis* in fungal diseases of the respiratory tract. The present study indicates that non-*albicans Candida* co-infect the lungs of HIV and AIDS patients with TB.

Data on the diversity of *Candida* species affecting human is increasing steadily, and several studies have highlighted the involvement of different species in human diseases in relation to pneumonia (Rello et al., 1998). Recent studies in 41 different countries have indicated increased rates of isolation of the common non-*albicans* species *C. glabrata* (10.2 to 11.7%), *C. tropicalis* (5.4 to 8.0%), and *C. parapsilosis* (4.8 to 5.6%) when the time periods 1997 to 2000 and 2005 to 2007 were compared (Pfaller et al., 2010). In the present study non-*albicans*

Candida spp. appeared to be important opportunistic pathogens causing respiratory infections in HIV patients in Vhembe district with *C. parapsilosis* (19%) being the most common followed by *C. krusei* (16%) while *C. albicans* was only the third most common species isolated from sputum samples. Studying yeast isolates from different types of samples from 24 hospitals in Taiwan, Yang et al., (2006) found that *C. albicans* (69.1%) was the most common species, followed by *C. tropicalis* (12.9%), *C. glabrata* (8.3%), *C. parapsilosis* (2.7%), *C. krusei* (0.6%), and others (6.4%), whereas Basu et al., (2003) also found that *C. albicans* (45%) was the predominant species isolated followed by *C. tropicalis* (24.7%) and *C. parapsilosis* (10.5%) from all clinical specimens (Sputum, blood, urine and others), except blood from which *C. krusei* was most frequently (38.4%) recovered. In a study on oropharyngeal candidiasis among HIV patients in Nigeria, *C. albicans* (40.5%) was the most frequently isolated species, while the non-*albicans* species included *C. tropicalis*, *C. Krusei*, *C. glabrata* and *C. neoformans* for species having up to 4 isolates (Enwuru et al., 2008). The contribution of these organisms to the pathogenicity of respiratory disease could not be established from present study since these were secondary to TB infections. Therefore further studies need to be conducted with emphasis on clinical presentation of the disease in order to determine the pathogenic impact of the fungal isolates.

The management of fungal infections among HIV and AIDS patients as well as immunocompetent patients includes the use of various antifungal agents including azoles and polyenes (Pappas et al., 2004). Fluconazole (FLC) belongs to the azoles and interferes with ergosterol biosynthesis by binding to the *ERG11* gene product, lanosterol 14- α -demethylase. In a study in Nigeria,

resistance to fluconazole was 22% (Enwuru et al., 2008). This prevalence is far much lower compared to the prevalence of resistance observed in the present study which was 74%. Although fluconazole had been shown to be very active against most clinical yeast organisms mostly *Candida* spp, with susceptibility levels of 90%, an increase in fluconazole resistance over time was seen with *C. parapsilosis*, *C. guilliermondii*, *Candida lusitanae*, *Candida sake*, and *Candida pelliculosa* (Pfaller et al., 2010). Among the emerging fluconazole-resistant species were *C. guilliermondii* (11.4% R), *Candida inconspicua* (53.2% R), *Candida rugosa* (41.8% R), and *Candida norvegensis* (40.7% R). In another study on the susceptibility of *Candida* spp. to amphotericin B and fluconazole, Yang et al. (2008) reported the prevalence of non-albicans *Candida* species had increased as compared to previous studies, and this was due to the frequent exposure of non-*albicans* to fluconazole which induces the exposed species to develop resistance. Resistance among fungal organisms to antifungal drug is often the result of multiple factors including the expression of efflux pumps in the fungal cell membrane, biofilm matrix permeability, and a stress response in the fungal cell (Niimi et al., 2010). Although several factors might be responsible for the high resistance of yeast isolates to fluconazole in the present study, frequent use of fluconazole in the treatment of fungal related infections among HIV and AIDS patients in the region might be an important cause of this high resistance.

The present study did not obtain clinical information such as the CD4 counts of the patients or the viral load. However, the potential effects of fungal infections in the lungs need to be clarified. In fact, many patients treated for TB in the hospitals are "smear negative" (Koole et al., 2011). This raises the possibility of other pathogens been involved in the symptoms experienced by the patients. Recent studies by Jarvis and colleague have demonstrated the disastrous consequences of pulmonary cryptococcosis misdiagnosed as smear-negative pulmonary tuberculosis with fatal consequences (Jarvis et al., 2010). The present study also demonstrates the high prevalence of *Cryptococcus neoformans* in sputum samples of HIV patients co-infected with TB and therefore supports the possibility of TB patients to be susceptible to other fungal infections as well or the possibility of these fungal infections being misdiagnosed in a limited number of cases as "smear negative TB". Further studies are needed to confirm the role of pulmonary fungal infections in "smear negative" patients.

The formation of biofilm is a major virulence factor in *C. albicans* pathogenesis and is related to drug resistance among these organisms. Studies by Nailis et al., (2010) indicated that sessile *C. albicans* cells show controlled regulation of gene expression, as they quickly mount a drug specific transcriptional response in the presence of high doses of antifungal agents. Biofilm production depends on the different species of *Candida*. In the

present study we found that 33% of *C. albicans* produced biofilm and appeared to be the most biofilm producing species when all the other *Candida* species were considered. In a study conducted by Demirbileki et al., (2007) the biofilm production rate of non-*albicans* (41%) was found higher than *albicans* (23%), and the difference was statistically significant ($p < 0.05$). We did not find any association between biofilm production and drug resistance in the present study as previously stipulated (Niimi et al., 2010). This difference could be due to factors that could be experimental or strain related. Studies on larger samples with different conditions might give more insight into the role of biofilm on drug resistance among yeast isolates in the Vhembe district.

C. neoformans is responsible for several syndromes of which the most important is cryptococcal meningitis followed by cryptococcal pneumonia (Shankar et al., 2006). Deok-Jong et al. (2010) in a study done in Mulago Hospital (Uganda) reported that pulmonary cryptococcosis was common in HIV patients suspected with tuberculosis and the median CD4 count among those with pulmonary cryptococcosis was 23 cells per microliter. In the present study *C. neoformans* was the most commonly isolated organism in sputum samples (28%) among patients with tuberculosis. Previous studies have indicated that the isolation of *C. neoformans* from bronchial secretion of HIV positive patients is a signal of disseminated cryptococcosis (Helou et al., 1999). Other types of *Cryptococcus* have also been reported in the sputum of AIDS patients. In Tamilnadu, India, a case of pulmonary cryptococcosis caused by *C. laurentii* in a diabetic AIDS patient who was on anti-tuberculosis and antiretroviral treatments was reported (Shankar et al., 2006). In the present study, the only species isolated was *C. neoformans*, however, no effort was made to further characterize the *Cryptococcus* spp. isolated.

C. neoformans biofilm producing strains have been shown to be more resistant to antifungal drugs than the non biofilm producing strains. Martinez and Casadevall, (2006) reported that the exposure of *C. neoformans* cells or preformed cryptococcal biofilms to fluconazole or voriconazole did not result in yeast growth inhibition and did not affect the metabolic activities of the biofilms, respectively. In the present study *C. neoformans* was resistant to all the drugs tested with the lowest resistance being observed to amphotericin B (31% resistance). Increased resistance could be associated with exposure to the drug as previously described by Sionov et al., (2009) who observed in their study that, upon exposure to stepwise increases in the concentration of FLC, subpopulations that could grow at higher concentrations emerged.

Conclusions

In conclusion, this study shows that HIV patients infected

with TB are often colonized with fungal organisms. These organisms might contribute to the exacerbation of the respiratory syndromes although further studies are needed to confirm this hypothesis. The most common opportunistic yeasts found in the respiratory tract of HIV patients co-infected with TB attending Hospital centers in Vhembe District, South Africa, are *C. neoformans*, *C. parapsilosis*, *C. krusei* and *C. albicans*. Amphotericin B was the most active drug against these opportunistic pathogens. This study further highlights the need for routine speciation and antifungal susceptibility testing on HIV patients. It also indicates the emergence of non-*albicans Candida* as potential important respiratory pathogens in HIV patients in Vhembe district, Limpopo province and more studies are needed to clarify the role of these fungal organisms in the clinical presentation of pneumonia in the target population. The identification of the infecting organisms and antifungal susceptibility testing will enhance the ability of clinicians to prescribe appropriate antifungal therapy. Further studies are needed to confirm the role of pulmonary fungal infections in “smear negative” patients.

ACKNOWLEDGEMENTS

The authors are very grateful to the Limpopo, Department of Health, in Polokwane for authorizing the study to be conducted in the hospitals. We are also grateful to the hospitals staff, management technicians and nurses as well as the patients who agreed to participate in the study. This study was funded by a grant from the National Research Foundation (NRF) and the Research and Publication committee of the University of Venda.

REFERENCES

- Alby K, Bennett RJ (2009). Stress-induced phenotypic switching in *Candida albicans*. *Mol. Biol. Cell*, 20(14): 3178-3191.
- Barnes RA (2008). Early diagnosis of fungal infection in immunocompromised patients. *J. Antimicrob. Chem.*, 61 (1): 3-6.
- Basu S, Gugnani HC, Joshi S, Gupta N (2003). Distribution of *Candida* species in different clinical sources in Delhi, India, and proteinase and phospholipase activity of *Candida albicans* isolates. *Rev. Iberoamer. Micol.*, 20(4): 137-140.
- Bazira J, Asiimwe BB, Joloba ML, Bwanga F, Matee MI (2011). *Mycobacterium tuberculosis* spoligotypes and drug susceptibility pattern of isolates from tuberculosis patients in South-Western Uganda. *BMC Infect. Dis.*, 11(1): 81.
- Blignaut E, Messer S, Hollis RJ, Pfaller M (2002). Antifungal susceptibility of South African oral yeast isolates from HIV/AIDS patients and healthy individuals. *Diagn. Microbiol. Infect. Dis.*, 44: 169-174.
- Cattamanchi A, Davis JL, Worodria W, den Boon S, Yoo S, Matovu J, Kiidha J, Nankya F, Kyeyune R, Byanyima P, Andama A, Joloba M, Osmond DH, Hopewell PC, Huang L (2009). Sensitivity and specificity of fluorescence microscopy for diagnosing pulmonary tuberculosis in a high HIV prevalence setting. *Int. J. Tuberc. Lung Dis.*, 13(9):1130-1136.
- Christensen GD, Simpson WA, Bisno AL, Beachery EH (1982). Adherence of slime producing strains of *Staphylococcus epidermidis* to smooth surface. *J. Infect. Dis. Immunol.*, 37: 318-426.
- Connolly JE Jr, McAdams HP, Erasmus JJ, Rosado-de-Christenson ML (1999). Opportunistic fungal pneumonia. *J. Thorac. Imaging*, 14(1): 51-62.
- Demirbileki M, Timurkaynak F, Can F, Azap O, Arslan H (2007). Biofilm production and antifungal susceptibility patterns of *Candida* species isolated from hospitalized patients. *Mikrobiyol. Bul.*, 41(2): 261-269.
- Deok-Jong Yoo S, Worodria W, Davis JL, Cattamanchi A, den Boon S, Kyeyune R, Kisebo H, Huang L (2010). The Prevalence and Clinical Course of HIV-Associated Pulmonary Cryptococcosis in Uganda. *J. Acquir. Immune Defic. Syndr.*, 54(3): 269-274.
- Egusa H, Soysa NS, Ellepola AN, Yatani H, Samaranyake LP (2008). Oral candidosis in HIV-infected patients. *Curr. HIV Res.*, 6(6): 485-499.
- Enwuru CA, Ogunledun A, Idika N, Enwuru NV, Ogbonna F, Aniedobe M, Adeiga A (2008). Fluconazole resistant opportunistic oropharyngeal *Candida* and non-*Candida* yeast-like isolates from HIV infected patients attending ARV clinics in Lagos, Nigeria. *Afr. Health Sci.*, 8(3): 142 – 148.
- Grange J, Adhikari M, Ahmed Y, Mwaba P, Dheda K, Hoelscher M, Zumla A (2010). Tuberculosis in association with HIV/AIDS emerges as a major nonobstetric cause of maternal mortality in Sub-Saharan Africa. *Int. J. Gynaecol. Obstet.*, 108(3):181-183.
- Helou S, Robles AM, Arechavala AI, Bianchi MH, Negroni R (1999). Respiratory cryptococcosis in HIV positive patients. *Rev. Iberoam. Micol.*, 16(3): 126-129.
- Heunis JC, Wouters E, Norton WE, Engelbrecht MC, Kigozi NG, Sharma A, Ragin C (2011). Patient- and delivery-level factors related to acceptance of HIV counseling and testing services among tuberculosis patients in South Africa: a qualitative study with community health workers and program managers. *Implement Sci.*, 6(1): 27.
- Jarvis JN, Wainwright H, Harrison TS, Rebe K, Meintjes G (2010). Pulmonary cryptococcosis misdiagnosed as smear-negative pulmonary tuberculosis with fatal consequences. *Int. J. Infect. Dis.*, 14 Suppl 3: e310-2.
- Karim SS, Churchyard GJ, Karim QA, Lawn SD (2009). HIV infection and tuberculosis in South Africa: an urgent need to escalate the public health response. *Lancet*, 374(9693): 921-933.
- Koole O, Thai S, Khun KE, Pe R, van Griensven J, Apers L, Van den Ende J, Mao TE, Lynen L (2011). Evaluation of the 2007 WHO Guideline to Improve the Diagnosis of Tuberculosis in Ambulatory HIV-Positive Adults. *PLoS One*, 6(4): e18502.
- Martinez LR, Casadevall A (2006). Susceptibility of *Cryptococcus neoformans* biofilms to antifungal agents in vitro. *Antimicrob. Agents Chemother.*, 50(3):1021-1033.
- Naidoo K, Naidoo K, Padayatchi N, Abdool Karim Q (2011). HIV-Associated Tuberculosis. *Clin. Dev. Immunol.*, pii: 585919: Epub 2010 Sep 13.
- Naillis H, Vandenbosch D, Deforce D, Nelis HJ, Coenye T (2010). Transcriptional response to fluconazole and amphotericin B in *Candida albicans* biofilms. *Res. Microbiol.*, 161(4): 284-92.
- Niimi M, Firth NA, Cannon RD (2010). Antifungal drug resistance of oral fungi. *Odontology*, 98(1): 15-25.
- Odds FC, Bernaerts R (1994). CHROMagar *Candida*, a new differential isolation medium for presumptive identification of clinically important *Candida* species. *J. Clin. Microbiol.*, 32(8): 1923-1929.
- Pappas PG, Rex JH, Sobel JD, Filler SG, Dismukes WE, Walsh TJ, Edwards JE (2004). Infectious Diseases Society of America. Guidelines for treatment of candidiasis. *Clin. Infect. Dis.*, 38(2): 161-189.
- Pfaller MA, Diekema DJ (2006). Rare and emerging opportunistic fungal pathogens: concern for resistance beyond *Candida albicans* and *Aspergillus fumigatus*. *J. Clin. Microbiol.*, 42: 4419–4431.
- Pfaller MA, Diekema DJ, Gibbs DL, Newell VA, Ellis D, Tullio V, Rodloff A, Fu W, Ling TA (2010). The Global Antifungal Surveillance Group: Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-Year Analysis of Susceptibilities of *Candida* Species to Fluconazole and Voriconazole Determined by CLSI Standardized Disk Diffusion. *J. Clin. Microbiol.*, Doi: 10.1128/JCM.02117-09.
- Rajasekaran S, Jeyaseelan L, Raja K, Ravichandran N (2009). Demographic and clinical profile of HIV infected children accessing

- care at Tambaram, Chennai, India. Indian J. Med. Res., 129: 42-49.
- Ramogale MR, Moodley J, Sebitloane MH (2007). HIV associated maternal mortality—primary causes of death at King Edward VIII Hospital, Durban. S. Afr. Med. J., 97(5): 363–366.
- Rello J, Esandi ME, Díaz E, Mariscal D, Gallego M, Vallès J (1998). The role of *Candida* sp isolated from bronchoscopic samples in nonneutropenic patients. Chest, 114(1): 146-149.
- Samie A, Barrett LJ, Bessong PO, Ramalivhana JN, Mavhandu LG, Njayou M, Guerrant RL (2010). Seroprevalence of *Entamoeba histolytica* in the context of HIV and AIDS: Case of the Vhembe district, Limpopo Province, South Africa. Ann. Trop. Med. Parasitol., 104 (1): 55–63.
- Shankar EM, Kumarasamy N, Bella D, Renuka S, Kownhar H, Suniti S, Rajan R, Rao UA (2006). Pneumonia and pleural effusion due to *Cryptococcus laurentii* in a clinically proven case of AIDS. Can. Respir. J., 13(5): 275-278.
- Sionov E, Chang YC, Garraffo HM, Kwon-Chung KJ (2009). Heteroresistance to fluconazole in *Cryptococcus neoformans* is intrinsic and associated with virulence. Antimicrob. Agents Chemother., 53(7): 2804-2815.
- Yang YL, Cheng WT, LoJH (2006). THE TSARY HOSPITALS: Distribution and antifungal susceptibility of *Candida* species isolated from different age populations in Taiwan. Med. Mycol., 44(3): 237-242.
- Yang YL, Wang AH, Wang CH, Cheng WT, Li SY, Lo HJ (2008). TSARY Hospitals: Susceptibilities to amphotericin B and fluconazole of *Candida* species in Taiwan Surveillance of Antimicrobial Resistance of Yeasts 2006. Diagn. Microbiol. Infect. Dis., 61(2): 175-178.
- Zumla A, Mwaba P, Huggett J, Kapata N, Chanda D, Grange J (2009). "Reflections on the white plague," Lancet Infect. Dis., 9(3): 197–202.